Abivax SA Sponsored ADR $ABVX Stock: CenterBook Partners LP Grows Holdings

CenterBook Partners LP raised its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 321.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 142,496 shares of the company’s stock after acquiring an additional 108,685 shares during the quarter. Abivax comprises 0.6% of CenterBook Partners LP’s holdings, making the stock its 28th largest position. CenterBook Partners LP’s holdings in Abivax were worth $14,110,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of the business. Eversept Partners LP boosted its stake in shares of Abivax by 42.0% in the first quarter. Eversept Partners LP now owns 934,423 shares of the company’s stock valued at $104,048,000 after buying an additional 276,589 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Abivax by 31.6% in the first quarter. Janus Henderson Group PLC now owns 878,829 shares of the company’s stock worth $98,007,000 after acquiring an additional 211,068 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Abivax by 40.9% in the 1st quarter. Bank of America Corp DE now owns 735,729 shares of the company’s stock valued at $81,923,000 after purchasing an additional 213,440 shares in the last quarter. Two Seas Capital LP acquired a new stake in shares of Abivax in the 3rd quarter valued at approximately $66,996,000. Finally, Orbimed Advisors LLC grew its holdings in shares of Abivax by 26.6% during the 1st quarter. Orbimed Advisors LLC now owns 465,700 shares of the company’s stock valued at $51,856,000 after purchasing an additional 97,800 shares during the last quarter. 47.91% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ABVX has been the subject of several research analyst reports. Wedbush lowered their price target on shares of Abivax from $118.00 to $96.00 and set a “neutral” rating for the company in a report on Wednesday, October 21st. Truist Financial cut their price objective on Abivax from $155.00 to $151.00 and set a “buy” rating on the stock in a report on Tuesday, September 22nd. Guggenheim reissued a “buy” rating and set a $175.00 price objective on shares of Abivax in a report on Tuesday, October 20th. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. Finally, Barclays reaffirmed an “overweight” rating and issued a $148.00 target price on shares of Abivax in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $155.00.

Abivax Stock Performance

Shares of ABVX stock traded up $1.55 during mid-day trading on Friday, hitting $85.73. The company’s stock had a trading volume of 827,191 shares, compared to its average volume of 1,072,878. The company has a market cap of $7.51 billion, a PE ratio of -14.15 and a beta of 1.36. The company’s fifty day simple moving average is $97.20 and its 200-day simple moving average is $113.33. Abivax SA Sponsored ADR has a 52 week low of $69.81 and a 52 week high of $148.83.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Monday, September 21st. The company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.79). The business had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $0.80 million. On average, equities analysts anticipate that Abivax SA Sponsored ADR will post -4.14 earnings per share for the current year.

Abivax Profile

Abivax SA (NASDAQ: ABVX) is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory and immune-mediated diseases. Headquartered in Paris, France, the company conducts research and clinical development aimed at addressing conditions with significant unmet medical needs.

Abivax’s lead investigational product is obefazimod, an oral small-molecule therapy designed to selectively increase levels of microRNA-124, a regulatory molecule involved in controlling inflammatory responses.